Eculizumab ( INN and USAN , trade name Soliris ) is a monoclonal antibody directed against the complement protein C5 . This antibody blocks the cleavage of C5 and halts the process of complement-mediated cell destruction. more

Eculizumab ( INN and USAN , trade name Soliris ) is a monoclonal antibody directed against the complement protein C5 . This antibody blocks the cleavage of C5 and halts the process of complement-mediated cell destruction. Eculizumab is a product of Alexion Pharmaceuticals and has been shown to be effective in treating paroxysmal nocturnal hemoglobinuria . [ 1 ] Eculizumab was approved by the United States Food and Drug Administration (FDA) on March 16 , 2007 and was later approved by the European Medicines Agency on June 20 , 2007 . less